Fexofenadine

• CAT Number: R001766
• CAS Number: 83799-24-0
• Molecular Formula: C32H39NO4
• Molecular Weight: 501.667
• Purity: ≥95%
• Storage: -20°C
• IUPAC Name: 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
• InChI: InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
• InChIKey: RWTNPBWLLIMQHL-UHFFFAOYSA-N
• SMILES: CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O

Fexofenadine is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever, nasal congestion, and urticaria. Fexofenadine is classified as a second-generation antihistamine because it is less able to pass the blood-brain barrier and cause sedation, compared to a first-generation antihistamines.

Reference

1:Fexofenadine, a putative in vivo P-glycoprotein probe, fails to predict clearance of the substrate tacrolimus in renal recipients. Vanhove T, Bouillon T, de Loor H, Annaert P, Kuypers DRJ.Clin Pharmacol Ther. 2017 Apr 24. doi: 10.1002/cpt.718. [Epub ahead of print] PMID: 28437851 2:Effect of Garlic, Gingko, and St. John/’s Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study. Turkanovic J, Ward MB, Gerber JP, Milne RW.Drug Metab Dispos. 2017 May;45(5):569-575. doi: 10.1124/dmd.116.073528. Epub 2017 Feb 10. PMID: 28188296 3:Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation. Bedada SK, Appani R, Boga PK.Drug Dev Ind Pharm. 2017 Jun;43(6):932-938. doi: 10.1080/03639045.2017.1285310. Epub 2017 Feb 5. PMID: 28102715 4:Influence of P-glycoprotein on the disposition of fexofenadine and its enantiomers. Li F, Howard KD, Myers MJ.J Pharm Pharmacol. 2017 Mar;69(3):274-284. doi: 10.1111/jphp.12687. Epub 2017 Jan 16. PMID: 28090646 5:Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S.Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. PMID: 28066101 Free PMC Article6:The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. Bedada SK, Boga PK.Eur J Clin Pharmacol. 2017 Mar;73(3):343-349. doi: 10.1007/s00228-016-2173-3. Epub 2016 Dec 15. PMID: 27981349 7:Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-Specific Release of Fexofenadine for Ulcerative Colitis. Dhaneshwar SS, Singh P.Curr Drug Deliv. 2016 Dec 5. [Epub ahead of print] PMID: 27919212 8:Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H1 receptor, COX-2, NF-κB, CCR1, chemokine CCL5/RANTES and interleukin-1β in PBMC allergic and non-allergic patients. Kordulewska NK, Kostyra E, Cieślińska A, Matysiewicz M, Fiedorowicz E, Sienkiewicz-Szłapka E.Immunobiology. 2017 Mar;222(3):571-581. doi: 10.1016/j.imbio.2016.11.004. Epub 2016 Nov 10. PMID: 27843000 9:Cytokine production by PBMC and serum from allergic and non-allergic subjects following in vitro histamine stimulation to test fexofenadine and osthole anti-allergic properties. Kordulewska NK, Kostyra E, Cieślińska A, Fiedorowicz E, Jarmołowska B.Eur J Pharmacol. 2016 Nov 15;791:763-772. doi: 10.1016/j.ejphar.2016.10.020. Epub 2016 Oct 15. PMID: 27756601 10:Design, characterization and in vitro evaluation of HPMC K100 M CR loaded Fexofenadine HCl microspheres. Arefin P, Hasan I, Reza MS.Springerplus. 2016 May 25;5(1):691. doi: 10.1186/s40064-016-2322-2. eCollection 2016. PMID: 27350925 Free PMC Article